Cellular Biomedicine Group (CBMG) currently reports a current cash of $26M as of September 2020. That compares with $29M in the prior-year period — down 10.4% year over year. Use the charts on this page to explore Cellular Biomedicine Group's current cash history and peer comparisons.

Cellular Biomedicine Group's current cash decreased from $29M to $26M — a 10.4% year-over-year decrease (period ending September 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cellular Biomedicine Group reported $26M in current cash as of September 2020. That compares with $29M in the prior-year period — down 10.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $26M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cellular Biomedicine Group, and consider following CBMG for alerts when major investors trade the stock.

Cellular Biomedicine Group is classified in the Healthcare sector. On current cash, it currently shows $26M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBMG with unrelated industries.